TPA
AZN icon

Trivium Point Advisory’s AstraZeneca AZN Stock Holding History

Trivium Point Advisory’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,569
Closed -$288K – 275
2025
Q4 		$288K Buy
+1,569
New +$275K 0.03% 289

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

Trivium Point Advisory's AZN Position: Q1 2026 in Review

Trivium Point Advisory sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,569 shares — an estimated $288K sold.

Trivium Point Advisory first reported a position in AZN in Q4 2025 and held it in 1 quarter. The position peaked at $288K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Trivium Point Advisory reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Trivium Point Advisory sold 1,569 AstraZeneca shares in Q1 2026, an estimated $288K.
  • Trivium Point Advisory first reported a position in AstraZeneca in Q4 2025 and held it in 1 quarter.
  • Trivium Point Advisory's AstraZeneca position peaked at $288K in Q4 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Trivium Point Advisory's 13F filing for Q1 2026, filed 21 Apr 2026.